ArticleJournal of molecular histology2026
ESPNP promotes cell migration and invasion in gastric cancer cells via regulation of epithelial-mesenchymal transition/Twist1.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the long non-coding RNA (lncRNA) ESPNP to elucidate its regulatory roles in gastric cancer (GC) cell proliferation, invasion, and metastatic potential. We performed RNA sequencing on gastric cancer liver metastasis (GCLM) tissues, gastric cancer tissues (GCT), and peritumoral tissues (PT) to identify differentially expressed lncRNAs. LncRNA ESPNP was highly expressed in GCLM and GCT, and was thus chosen for further analysis. Cell viability was assessed using the CCK-8 assay, whereas Transwell and wound-healing assays were used to evaluate invasive and migratory capacities. The results revealed that transfection with an ESPNP small interfering RNA (siRNA) significantly suppressed the viability, invasion, and migration of GC cells. Furthermore, compared with transfection with a Twist1 overexpression plasmid alone, co-transfection with the Twist1 plasmid and ESPNP siRNA significantly reduced GC cell viability as well as invasive and migratory capacities. In addition, in vivo experiments demonstrated that ESPNP silencing markedly inhibited tumor growth. Terminal deoxynucleotidyl transferase nick-end-labeling and Ki67 staining also showed that ESPNP short hairpin RNA treatment enhanced cell apoptosis and reduced cell proliferation. Taken together, our study demonstrated that ESPNP promotes GC progression by enhancing proliferation, invasion, metastasis, and epithelial-mesenchyme transition, suggesting its potential as a prognostic biomarker and therapeutic target in GC.
Indexed as
Identifiers
41712075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.